Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system. This groundbreaking technology represents a novel approach to industrial-scale protein production, offering unique advantages over traditional mammalian cell systems. Protalix’s innovative platform enables the development of high-quality therapeutic proteins with potentially reduced costs and improved scalability.
Core Business Model and Revenue Streams
Protalix generates revenue through a combination of product sales, licensing agreements, and strategic partnerships. Its lead products include taliglucerase alfa (marketed as Elelyso® by Pfizer outside Brazil and Uplyso® in Brazil) for Gaucher disease and Elfabrio® (pegunigalsidase alfa), a PEGylated enzyme replacement therapy for Fabry disease, developed in collaboration with Chiesi Global Rare Diseases. These partnerships enable Protalix to leverage the global distribution networks of its collaborators while focusing on its core competency: innovative drug development. The company also earns revenue from technology transfer agreements, such as its collaboration with Fundação Oswaldo Cruz in Brazil.
Innovative Technology Platform: ProCellEx®
At the heart of Protalix’s operations is its proprietary ProCellEx® protein expression system, the first plant cell-based platform to receive FDA approval for a recombinant therapeutic protein. ProCellEx® uses plant cells grown in suspension to produce therapeutic proteins, offering a cost-effective and scalable alternative to traditional methods. This platform has been instrumental in the development of Protalix’s pipeline, enabling the creation of proprietary and biosimilar versions of recombinant proteins targeting rare and orphan diseases.
Product Portfolio and Pipeline
Protalix’s commercial portfolio includes:
- Taliglucerase alfa – An enzyme replacement therapy for Gaucher disease, co-developed with Pfizer.
- Elfabrio® – Approved for Fabry disease, developed in partnership with Chiesi Farmaceutici.
The company’s robust pipeline features several promising candidates, including:
- PRX–115 – A plant cell-expressed recombinant PEGylated uricase for severe gout, currently advancing to Phase II clinical trials.
- PRX–119 – A long-acting DNase I candidate targeting NETs-related diseases, designed for enhanced half-life and efficacy.
These developments underscore Protalix’s commitment to addressing unmet medical needs in rare diseases.
Strategic Partnerships and Market Position
Protalix has established key collaborations with industry leaders such as Pfizer and Chiesi Farmaceutici, leveraging their expertise in global commercialization and regulatory navigation. These partnerships enable Protalix to focus on its innovation-driven R&D efforts while ensuring broad market access for its products. The company’s ability to secure FDA and EMA approvals for its therapies highlights its competitive edge in regulatory compliance and product quality.
Challenges and Competitive Landscape
Operating in the biopharmaceutical sector, Protalix faces challenges such as intense competition, regulatory complexities, and geopolitical risks given its location in Israel. However, its unique ProCellEx® platform, focus on rare diseases, and strategic alliances position it favorably within the industry. By addressing niche markets with high unmet needs, Protalix minimizes direct competition and establishes itself as a key player in the rare disease segment.
Conclusion
Protalix BioTherapeutics combines cutting-edge technology, strategic partnerships, and a focus on rare diseases to deliver innovative therapeutic solutions. Its proprietary ProCellEx® system not only differentiates the company but also provides a scalable and cost-effective platform for future growth. With a strong product portfolio, a promising pipeline, and established global partnerships, Protalix is well-positioned to make a significant impact in the biopharmaceutical industry.
Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for Q1 2023, ending March 31, 2023, on May 4, 2023. The company, known for its proprietary ProCellEx® plant cell-based protein expression system, will host a conference call to discuss these results and recent corporate and regulatory updates at 8:30 a.m. EDT. Interested investors can access the conference call via toll-free numbers or the provided webcast links. Protalix is notable for being the first to receive FDA approval for a protein produced through a plant cell-based expression system and continues to develop several therapeutic proteins targeting established markets, including treatments for Fabry disease and severe gout.
Protalix BioTherapeutics (PLX) announced the dosing of the first patient in its phase I First in Human (FIH) clinical trial of PRX-115, a PEGylated uricase aimed at treating severe gout. This double-blind, placebo-controlled study will assess safety, pharmacokinetics, and pharmacodynamics in approximately 56 patients with high uric acid levels. The trial is taking place at New Zealand Clinical Research under regulatory guidelines and involves single ascending doses of PRX-115 versus placebo. The CEO emphasized the company's commitment to addressing unmet medical needs and continuing patient enrollment.
Protalix BioTherapeutics (NYSE American:PLX) announced that it has no cash deposits or financial relationships with Silicon Valley Bank or Signature Bank, following their recent closures. The company maintains most of its cash in major U.S. banks and does not expect any operational impact from the banks' closure. Protalix monitors the situation regarding potential effects on partners and suppliers. The company is known for its recombinant therapeutic proteins produced via its ProCellEx® system, with FDA-approved products like taliglucerase alfa and several candidates in development targeting various diseases.
Protalix BioTherapeutics (NYSE: PLX) reported strong financial results for the year ending December 31, 2022, with revenues of $25.3 million, a 51% increase from 2021. This growth was driven by sales to Pfizer, Brazil, and Chiesi. The EMA has given a positive opinion for PRX-102, recommending marketing authorization for Fabry disease, with a final decision expected in May 2023. The FDA accepted the resubmitted biologics license application for PRX-102 with an action date also set for May 9, 2023. Despite a net loss of $14.9 million, a significant reduction from a $27.6 million loss in 2021, the company remains optimistic about its future prospects and continued advancements in its pipeline.
On February 24, 2023, Chiesi Global Rare Diseases and Protalix BioTherapeutics (NYSE American: PLX) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa), aimed at treating adult Fabry disease patients. This groundbreaking enzyme replacement therapy demonstrates a favorable benefit-risk profile based on comprehensive clinical studies. A final decision by the European Commission is expected in May 2023, which could lead to significant advancements in treatment options for those suffering from this rare disease.
Protalix BioTherapeutics (NYSE American: PLX) has announced its participation in the 19th Annual WORLD Symposium™ 2023, scheduled for February 22–26, 2023, at the Hilton Orlando, Florida. Protalix will host an informational booth at the event. Its partner, Chiesi Global Rare Diseases, will present on key topics, including PRX–102, an investigational treatment for Fabry disease. Presentations and abstracts will be accessible on Protalix's website. Protalix is renowned for its ProCellEx® system, enabling the production of recombinant therapeutic proteins and has a diverse pipeline targeting various diseases.
Protalix BioTherapeutics (NYSE: PLX) will announce its fiscal year 2022 financial results and provide a business update on February 27, 2023. The event will include a conference call at 8:30 a.m. EST, where management will discuss the financial outcomes and recent corporate developments. The company's proprietary ProCellEx® system produces therapeutic proteins, with taliglucerase alfa being its first FDA-approved product. Protalix's pipeline includes products targeting key health issues like Fabry disease and severe gout, indicating ongoing investment in innovative biopharmaceuticals.
FAQ
What is the current stock price of Protalix Biother (PLX)?
What is the market cap of Protalix Biother (PLX)?
What is Protalix BioTherapeutics' core technology?
What are Protalix's main products?
How does Protalix generate revenue?
What diseases does Protalix target?
What makes ProCellEx® unique?
Who are Protalix's key partners?
What is PRX–115?
What challenges does Protalix face?
What is Elfabrio® used for?
How does Protalix differentiate itself in the market?
